The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Effect of cilazapril on glucose tolerance and lipid profile in hypertensive patients with non-insulin-dependent diabetes mellitus.
Hypertension frequently complicates diabetes mellitus and is associated with an increased incidence of cardiovascular and microvascular complications . Angiotensin-I converting enzyme ( ACE ) inhibitors are effective antihypertensive agents and it has been suggested that they may improve glucose tolerance . We performed a double-blind , r and omized study comparing treatment for 8 weeks with cilazapril , a new ACE inhibitor , or placebo on metabolic variables in 22 hypertensive non-insulin-dependent diabetes mellitus ( NIDDM ) patients . At week 8 no significant changes in fasting plasma glucose , fasting plasma insulin , haemoglobin A1 and plasma lipids had occurred . The areas under the glucose [ placebo ( mean + /- SD ) : 10.7 + /- 3.27 and 10.6 + /- 2.53 ; cilazapril : 11.9 + /- 3.23 and 12.1 + /- 2.9 mmol/l per 180 min at 0 and 8 weeks , respectively ] and insulin curve  [ placebo ( median and range ) : 47.4 ( 31.4 - 165.1 ) and 65.3 ( 16.8 - 190.8 ) ; cilazapril : 51.1 ( 23.8 - 132.0 ) and 57.6 ( 29.0 - 150.1 ) mU/l per 180 min at 0 and 8 weeks , respectively ] after a st and ardized oral liquid test meal were unaltered . A significant decrease in mean arterial blood pressure was observed after cilazapril ( 122 + /- 8.6 and 106 + /- 8.3 mmHg at 0 and 8 weeks , respectively ) , in contrast to placebo ( 122 + /- 6.7 and 120 + /- 6.9 mmHg at 0 and 8 weeks , respectively ) . In conclusion , cilazapril does not affect metabolic control in hypertensive NIDDM patients , whereas it effectively reduces blood pressure
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .